Johnson Matthey and Rennovia Announce License Agreement With ADM For Glucaric Acid Technology

News   Feb 24, 2017 | Original Story From Johnson Matthey

 
Johnson Matthey and Rennovia Announce License Agreement With ADM For Glucaric Acid Technology
 
 
 
 

RELATED ARTICLES

360 New Disease Models Identified in Lab Mouse Study

News

The research, which generated over 20 million pieces of data, has found 360 new disease models and provides 28,406 new descriptions of the genes’ effects on mouse biology and disease.

READ MORE

LifeArc, Dstl and CDRD Collaborate to Identify Antibacterial Drug Targets

News

Novel approach capitalises on commonality across pathogens.

READ MORE

FDA to Fast Track Designation for Pfizer and Lilly's Tanezumab

News

Global Phase 3 program is studying potential new treatment option for millions of people living with chronic pain associated with osteoarthritis and chronic low back pain.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE